← Back to Search

18F-TFB PET Imaging for Thyroid Cancer

N/A

Waitlist Available

Led By Ravinder Grewal, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age ≥ 18 years

Patients must have histologically or cytologically confirmed thyroid carcinoma of follicular origin (including papillary and its respective variants)

Must not have

Patients unable to follow a low iodine diet or requiring medication with high content in iodide (amiodarone)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 day following scan

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a new scan that can quickly show how much radioactive iodine thyroid cancer will absorb. It aims to help doctors plan treatment more effectively without interfering with the therapy. The study focuses on patients with thyroid cancer to improve their treatment outcomes.

Who is the study for?

This trial is for adults over 18 with thyroid cancer of follicular origin, who can sign consent and follow a low iodine diet. They must have normal organ function, not be pregnant or breastfeeding, use contraception if fertile, and have tumors visible on imaging tests. Exclusion includes uncontrolled illness, recent iodinated contrast exposure without clearance, and non-compliance.

What is being tested?

The study tests a new PET imaging technique using 18F-Tetrafluoroborate (18F-TFB) to predict radioactive iodine uptake in thyroid cancer more quickly than current methods without affecting therapeutic radioactive iodine uptake.

What are the potential side effects?

While the trial description does not specify side effects of the intervention directly, typical PET scan-related side effects may include discomfort at injection site or allergic reaction to tracers.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

My thyroid cancer is confirmed to be of follicular origin, including papillary types.

Select...

I can take care of myself but might not be able to do heavy physical work.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I cannot follow a low iodine diet or need medication high in iodide.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 day following scan

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 day following scan

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 day following scan for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Safety Outcome Measures (CTCAE v4) severity of adverse events

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: PET Imaging With 18F-TFBExperimental Treatment2 Interventions

The intervention is the administration of a single dose of approximately 5-10 mCi 18F-TFB (mass \<= 50 μg) for imaging purposes. This will be followed by a 30 minute dynamic PET/CT study immediately after injection, at 60 minutes (+/- 10 min) and 4 hours (+/- 15 min) post injection. The second and third scan will last up to 30 minutes.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

PET Imaging

2008

Completed Phase 3

~370

0 / 4Eligibility criteria met